Bristol Myers Squibb Announces Dividend Increase




Bristol Myers Squibb Announces Dividend Increase

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on February 2, 2026, to stockholders of record at the close of business on January 2, 2026.

This quarterly dividend represents a 1.6% increase over last year’s quarterly rate of sixty-two cents ($0.62) per share. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2026 is $2.52 per share. This marks the 17^th consecutive year that the company has increased its dividend and the 94^th consecutive year that the company has paid a dividend.

In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable on March 2, 2026, to stockholders of record at the close of business on February 3, 2026.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook, and Instagram.

corporatefinancial-news

Contacts

Media Relations:
media@bms.com

Investor Relations:
investor.relations@bms.com

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders




Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$QNCX #biotech–Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication of a summary of early-stage clinical studies of its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patient’s own red blood cells), in pulmonary and inflammatory bowel disorders (IBD) in the scientific journal Frontiers in Drug Delivery.

Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “This new Frontiers in Drug Delivery publication highlights the potential for clinical utility of our lead asset, eDSP, across pulmonary and IBD indications. The purpose of these prior studies was to demonstrate that eDSP can be delivered at efficacious doses while avoiding the frequent and debilitating common toxicities associated with chronic corticosteroid therapy. Importantly, it also speaks to the potential of eDSP to transform treatment paradigms across multiple diseases where chronic corticosteroid treatment is – or has the potential to become – the standard of care. As we rapidly approach topline results in the middle of the first quarter of 2026 for our Phase 3 NEAT study of eDSP in Ataxia-Telangiectasia (A-T), we believe these data further underscore not only the ability of eDSP to deliver corticosteroid efficacy without toxicities, but also highlight the significant pipeline expansion opportunities that lie ahead of Quince, assuming positive NEAT results.”

Frontiers in Drug Delivery Publication Highlights

The Frontiers in Drug Delivery publication entitled Use of Encapsulated Dexamethasone Sodium Phosphate (eDSP) in Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, and Inflammatory Bowel Disorders summarizes early-stage studies of eDSP conducted across eight clinical trials in patients with pulmonary and IBD.

Highlights include:

• Broad application of eDSP across multiple disease indications: Early-stage clinical studies investigated eDSP in patients, whose age ranged from five to 83 years, with chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), Crohn’s disease (CD), and ulcerative colitis (UC). DSP was loaded into autologous erythrocytes ex vivo and reinfused every two weeks or monthly with follow-ups that ranged from one to 24 months.
• Encouraging results in pulmonary and IBD: eDSP resulted in improved FEV1 and reduced infections in CF patients and improved symptoms in COPD with markedly reduced corticosteroid doses. In IBD, eDSP at low doses enabled corticosteroid withdrawal in 60% to 78% of patients and achieved remission in pediatric and adult CD and UC. Importantly, adverse toxicity effects typical of corticosteroids were notably absent while pharmacokinetic studies documented persistence of DSP levels up to 28 days post-infusion. Notably, the mean dose used in these early trials did not exceed 10 mg of eDSP per infusion suggesting that glucocorticoid receptor occupation could be achieved with a low eDSP dose.
• eDSP feasibility and tolerability across wide age range: Early studies demonstrate that eDSP is a feasible and well-tolerated treatment in children and older patients, delivering low-dose corticosteroids with prolonged therapeutic levels. These findings support further development of erythrocyte-based drug delivery for chronic inflammatory diseases in patients with corticosteroid-sensitive or corticosteroid-dependent disease.

About eDSP

eDSP is comprised of dexamethasone sodium phosphate (DSP) encapsulated in a patient’s own red blood cells (autologous erythrocytes). DSP is a corticosteroid well known for its anti-inflammatory properties as well as its dose-limiting toxicity due to adrenal suppression. The eDSP System is designed to provide the efficacy of corticosteroids and to reduce or eliminate the significant adverse effects that accompany chronic use of corticosteroid treatment.

eDSP leverages Quince’s proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. Red blood cells have several characteristics that make them a potentially effective vehicle for drug delivery, including potentially better tolerability, enhanced tissue distribution, reduced immunogenicity, and prolongation of circulating half-life. Quince’s AIDE technology is designed to harness these benefits to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response.

Currently, Quince is advancing its pivotal Phase 3 NEAT (Neurological Effects of eDSP in Subjects with A–T; NCT06193200/IEDAT-04-2022) clinical trial of eDSP in patients with Ataxia-Telangiectasia (A-T). a rare inherited autosomal recessive neurodegenerative and immunodeficiency disorder. The NEAT study is an international, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the neurological effects of eDSP in patients with A-T. This study consists of two cohorts randomized (1:1) between eDSP or placebo and treatment includes six infusions scheduled once every 21 to 30 days. The primary efficacy endpoint will be measured by the change from baseline to last efficacy visit using the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS) compared to placebo.

The company expects to report topline results from its Phase 3 NEAT clinical trial in the middle of the first quarter of 2026.

About Quince Therapeutics

Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube.

Forward-looking Statements

Statements in this news release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as “believe,” “may,” “should,” “expect,” “anticipate,” “plan,” “believe,” “estimated,” “potential,” “intend,” “will,” “can,” “seek,” or other similar words. Examples of forward-looking statements include, among others, statements relating to the timing, success, and reporting of results of the clinical trials and related data, including expected timing and outcome of Phase 3 NEAT topline results; ; current and future clinical development of eDSP, including for the potential treatment of Ataxia-Telangiectasia (A-T), Duchenne muscular dystrophy (DMD), pulmonary and inflammatory bowel disorders, and other potential indications; planned regulatory agency submissions and clinical trials and timeline, prospects, and milestone expectations; and potential benefits of eDSP and the company’s market opportunity. Forward-looking statements are based on Quince’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 24, 2025, Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law.

Contacts

Media & Investor Contact:
Stacy Roughan

Quince Therapeutics, Inc.

Vice President, Corporate Communications & Investor Relations

ir@quincetx.com

Curebound Awards $8.5 Million for 23 Cancer Research Studies, Including $1 Million Cure Prize




Curebound Awards $8.5 Million for 23 Cancer Research Studies, Including $1 Million Cure Prize

Philanthropic organization has awarded $51.5 million in cancer research grants to date with one vision: cures in our lifetime.

SAN DIEGO–(BUSINESS WIRE)–#AI—Curebound, a philanthropic organization that fundraises for and invests in innovative cancer research, today announced it has awarded 23 new grants totaling $8.5 million, including a $1 million Cure Prize, to advance promising cancer research programs.

Curebound’s Scientific Advisory Board, together with more than 100 scientific peer reviewers across the nation, evaluated hundreds of applications for Curebound grant programs – Catalyst, Discovery, Equity, Targeted Grants and Cure Prize – across key research pillars, including:

• Cancer Risk Detection
• Novel Approaches + Therapeutics
• Personalized Immunotherapy
• Cancer Community Equities
• Childhood Cancers

“Curebound identified these recipients based on their scientific strengths and ability to translate research breakthroughs into life-saving treatments quickly. We are grateful to the scientists nationwide who volunteered to evaluate hundreds of grant applications to select these 23 exciting cancer studies,” said Curebound Chief Science Advisor Ezra Cohen, MD, FRCPSC, FASCO.

2025 Curebound $1 Million Cure Prize

The Curebound Cure Prize is awarded for groundbreaking, collaborative and translational cancer research with near-term clinical application.

• Ludmil Alexandrov, PhD, UC San Diego; Diane Simeone, MD, UC San Diego; Adam Yala, PhD, UC Berkely; Karandeep Singh, MD, UC San Diego – Multi-modal artificial intelligence framework for early detection of pancreatic cancer

2025 Targeted Grant Recipients

Curebound Targeted Grants provide $500,000 each to research projects that are closer to clinical stages. Interdisciplinary collaboration is required to qualify and to ensure each project is geared toward translational application.

• David Cheresh, PhD, UC San Diego; Andrew Lowy, MD, UC San Diego – A human bispecific antibody to target pancreatic cancer stroma
• Steven Olson, Sanford Burnham Prebys; Dan Theodorescu, MD, PhD, University of Arizona – Discovery of NPEPPS inhibitors for the treatment of muscle-invasive bladder cancer
• Ronald Evans, PhD, The Salk Institute; Herve Tiriac, PhD, UC San Diego; Jonathan Weitz, PhD, UC San Diego; Scott Kopetz, MD, PhD, University of Texas MD Anderson – Intercepting colorectal cancer growth and therapeutic resistance through inhibition of protein fatty acid diacylation
• Rebecca Rakow-Penner, MD, PhD, UC San Diego; Christopher Millan, PhD, Beken Bio; Jingjing Zou, PhD, UC San Diego; Michael McHale, MD, UC San Diego – Ovarian cancer comprehensive screening and risk assessment with extracellular vesicle circulating blood tumor marker and MRI
• Fleur Ferguson, PhD, UC San Diego; Andrew Lowy, MD, UC San Diego; Anne Bang, PhD, Sanford Burnham Prebys; Eric Wang, PhD, Sanford Burnham Prebys; Jeremiah Momper, PhD, UC San Diego; Uri Manor, PhD, UC San Diego – Overcoming K-ras inhibitor resistance in PDAC
• Andrew Lowy, MD, UC San Diego; Yuan Chen, PhD, UC San Diego – SUMO Inhibition and Irinotecan: A Novel Synergistic Combination for Pancreatic Cancer Therapy
• Sumit K. Chanda, PhD, Scripps Research; Nikunj Shukla, UC San Diego; Sunnie Yoh, PhD, Scripps Research – Targeted immunopotentiation of neoantigen vaccines using innate immune agonists
• Charles Spruck, PhD, Sanford Burnham Prebys; Angela Liou, MD, Sanford Burnham Prebys; Eduard Sergienko, Sanford Burnham Prebys; Jon Covel, PhD, Sanford Burnham Prebys – Therapeutic targeting of immunomodulator FBXO44 in cancer

2025 Discovery Grant Recipients

Curebound Discovery Grants are one-time seed grants of $250,000 for early-phase studies that require interinstitutional collaboration and have the potential to open new frontiers in cancer science.

• Kelly Kersten, PhD, Sanford Burnham Prebys; Christina Towers, PhD, The Salk Institute – Elucidating how tumor mitochondrial transfer affects macrophage function in cancer
• Mitchell Kronenberg, PhD, La Jolla Institute for Immunology; Anusha Ganesan, MD, PhD, Rady Children’s Hospital; Hilde Cheroutre, PhD, La Jolla Institute for Immunology; Kyu Hye Chun, PhD, UC San Diego and La Jolla Institute for Immunology; Nicolas Thiault, PhD, La Jolla Institute for Immunology – Enlisting cytotoxic CD4+ T cells to fight childhood cancers
• Maximiliano A. D’Angelo, PhD, Sanford Burnham Prebys; Hatim Husain, MD, UC San Diego; Susanne Heyen-Genel, PhD, Sanford Burnham Prebys – Modulating Nup37 for novel cancer therapies
• Ronald Evans, PhD, The Salk Institute, Dannielle Engle, PhD, The Salk Institute; Herve Tiriac, PhD, UC San Diego – Overcoming stromal barriers to KRAS inhibition in pancreatic cancer with VDR agonist therapy
• Tony Hunter, PhD, The Salk Institute; Herve Tiriac, PhD, UC San Diego; Jonathan Weitz, PhD, UC San Diego; Yuan Sui, PhD, The Salk Institute – Perturbing the OSM-OSMR signaling axis in pancreatic ductal adenocarcinoma (PDA)
• Xueqin Sun, PhD, Sanford Burnham Prebys; Eduard Sergienko, PhD, Sanford Burnham Prebys; Frank Furnari, PhD, UC San Diego – Targeting a novel epigenetic vulnerability in glioblastoma
• Frank Furnari, PhD, UC San Diego; Raghavendra Vadla, PhD, UC San Diego; Susan Kaech, PhD, The Salk Institute – Targeting BRD2 to block therapy-induced reprogramming and immune evasion in glioblastoma
• Lukas Chavez, PhD, Sanford Burnham Prebys; Megan Paul, MD, Rady Children’s Hospital; Susanne Heyen-Genel, PhD, Sanford Burnham Prebys – Targeting ecDNA in high-risk medulloblastoma: A high-throughput assay to discover novel therapeutic probes
• Andrew Lowy, MD, UC San Diego; Herve Tiriac, PhD, UC San Diego; Ian Pass, PhD, Sanford Burnham Prebys – Targeting MICAL2 for pancreatic cancer therapy
• Robert Signer, PhD, UC San Diego; Helena Yu, MD, UC San Diego – The role of proteostasis pathways in pediatric leukemia

2025 Catalyst Grant Recipient

Curebound Catalyst Grants provide $250,000 of non-dilutive funding for early-stage companies to conduct research that addresses critical challenges in cancer prevention, detection or treatment and demonstrates opportunity to advance swiftly to the clinic.

• Michael Kelner, MD, Illudent, Inc.; Sean Uryu, Illudent; Venkata Kotaraju, Illudent – Illudent Therapeutics: Precision small-molecule targeting cancers deficient in nucleotide-excision repair

2025 Equity Grant Recipients

Curebound Equity Grants of $250,000 fund a broad range of research focused on advancing cancer care in medically underrepresented and underserved communities, with the goal of improving access, outcomes and equity.

• Brent Rose, MD, UC San Diego; Corinne McDaniels-Davidson, PhD, San Diego State; Edmund Qiao, MD, UC San Diego; Matthew Banegas, PhD; UC San Diego; Michelle Johnson, MD; UC San Diego – Addressing cancer disparities through pre-diagnostic care: A SEER-Medicare analysis of prostate, breast, and colorectal cancer
• Joshua Demb, PhD, UC San Diego; Linda Lara-Jacobo, PhD, San Diego State; Nicolas Lopez-Galvez, PhD, San Diego State – Promotora-led cancer prevention in the fields: Linking environmental pollutants and GI cancer risk in Imperial Valley
• Sharon Choi, MD, PhD, UC San Diego; Humberto Prada, PhD, San Diego State; Noe Crespo, PhD, San Diego State; Rana McKay, MD, UC San Diego – Structured exercise and nutritional guidance in Hispanic/Latino men with prostate cancer: A pilot study of SALUD-PC

“This $8.5 million in funding will support diverse, innovative and highly promising cancer research efforts,” said Curebound CEO Anne Marbarger. “None of this would be possible without our committed donors and the incredible scientific advisors who volunteer their time to rigorously review and select the studies Curebound funds. We’re proud to support these talented scientists and research teams and look forward to the progress their work will bring for people living with cancer.”

To see the completed list of 2025 Curebound research grant recipients click here. To learn more about donating, visit www.curebound.org/get-involved. To apply for Curebound funding, visit www.curebound.org/what-we-do.

About Curebound

Curebound fundraises for and invests in cancer research with the power to save lives. Through collaborative grants, corporate partnerships, and strategic investments, Curebound accelerates better prevention, detection, and treatments for cancer. Headquartered in the major U.S. biotech hub of San Diego, amid 3,000+ life sciences companies, leading health systems, and world-class research institutions, Curebound partners with these organizations to forge interdisciplinary collaboration, foster knowledge sharing, and fund pioneering cancer research. So far, Curebound has funded $51.5 million in cancer research, awarding 170 study grants for 23 types of pediatric and adult cancers. This work has resulted in 30 expanded clinical trials reaching 1,864 patients and has spurred $161 million in follow-on funding for Curebound-supported investigators. Cancer is relentless – so is Curebound. Join us at www.curebound.org.

Contacts

Media Contact:

Hilary McCarthy

774.364.1440

Hilary@clearpointagency.com

IVD Raw Materials Industry Presents $35.8 Billion Valuation by 2030 – Expansion of POC and Home Diagnostics Strengthens Need for High-Quality Antibodies, Antigens, and Buffers – ResearchAndMarkets.com




IVD Raw Materials Industry Presents $35.8 Billion Valuation by 2030 – Expansion of POC and Home Diagnostics Strengthens Need for High-Quality Antibodies, Antigens, and Buffers – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “IVD Raw Materials – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering.

The global market for IVD Raw Materials was valued at US$27.7 Billion in 2024 and is projected to reach US$35.8 Billion by 2030, growing at a CAGR of 4.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Growth in the IVD raw materials market is driven by several factors including rising global demand for diagnostic testing, increasing complexity of assay formats, and heightened regulatory scrutiny of material quality. Advances in recombinant production, synthetic chemistry, and expression systems are enabling reliable, scalable supply of high-performance components.

End-use expansion in molecular diagnostics, infectious disease testing, and personalized medicine is creating recurring demand for highly specific and stable raw materials. Emergence of new pathogens, focus on decentralized testing, and growing investment in lab infrastructure are further boosting usage. As diagnostics become central to preventive and precision medicine, the need for high-quality IVD raw materials continues to grow in both established and emerging healthcare markets.

Scope of the Report

The report analyzes the IVD Raw Materials market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below:

• Segments: Product (IVD Antibody & Antigens, IVD Enzymes, IVD Proteins, IVD Biological Buffers, Other Products); Technology (Clinical Chemistry Technology, Immunochemistry Technology, Molecular Diagnostics Technology, Other Technologies); End-Use (Pharma & Biotech Companies End-Use, Diagnostic Laboratories End-Use, Other End-Uses).
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the IVD Antibody & Antigens segment, which is expected to reach US$13.0 Billion by 2030 with a CAGR of a 3.8%. The IVD Enzymes segment is also set to grow at 5.0% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $7.6 Billion in 2024, and China, forecasted to grow at an impressive 7.8% CAGR to reach $7.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Key Questions Answered:

• How is the Global IVD Raw Materials Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Aalto Bio Reagents Ltd., AMSBIO (AMS Biotechnology), BBI Solutions, Bio-Rad Laboratories, Inc., Bio-Check (UK) Ltd and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 39 companies featured in this IVD Raw Materials market report include:

• Aalto Bio Reagents Ltd.
• AMSBIO (AMS Biotechnology)
• BBI Solutions
• Bio-Rad Laboratories, Inc.
• Bio-Check (UK) Ltd
• Bioporto Diagnostics
• Diarect AG
• EastCoast Bio
• Fitzgerald Industries Intl.
• Fujirebio
• HyTest Ltd
• Jena Bioscience GmbH
• Medix Biochemica
• Meridian Bioscience, Inc.
• MyBiosource, Inc.
• QuidelOrtho Corporation
• RayBiotech, Inc.
• Rockland Immunochemicals, Inc.
• Scripps Laboratories, Inc.
• Sekisui Diagnostics

Key Attributes

Market Overview

• Influencer Market Insights
• World Market Trajectories
• Tariff Impact on Global Supply Chain Patterns
• IVD Raw Materials – Global Key Competitors Percentage Market Share in 2025 (E)
• Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)

Market Trends & Drivers

• Rising Demand for In Vitro Diagnostics Across Infectious Disease, Cancer, and Genetic Testing Drives Consumption of Raw Materials
• Expansion of Point-of-Care and Home Diagnostics Strengthens Need for High-Quality Antibodies, Antigens, and Buffers
• OEM Focus on Recombinant Protein Engineering and Monoclonal Antibody Production Enhances Specificity and Stability
• Growth in Molecular Diagnostics and PCR-Based Assays Throws Spotlight on High-Fidelity Enzymes and Primers
• Increasing Emphasis on Supply Chain Resilience and Material Traceability Supports Strategic Sourcing of IVD Inputs
• OEM Investment in GMP-Compliant Raw Material Manufacturing Improves Quality Assurance for Diagnostic Kit Producers
• Rising Adoption of Multiplex Assays and Rapid Diagnostic Tests Fuels Need for Custom Coating and Blocking Reagents
• OEM Development of Bulk Supply Agreements With Test Kit Manufacturers Enhances Scalability and Delivery Reliability
• Growth in Companion Diagnostics and Personalized Medicine Expands Use of Specialized Biomarker Reagents
• OEM Innovation in Lyophilized and Room-Temperature Stable Raw Materials Supports Distribution in Low-Resource Settings

For more information about this report visit https://www.researchandmarkets.com/r/uevenz

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Cocaine Use Disorder Market Analysis, Trends and Outlook 2025-2032 by Treatment Modality, Treatment Setting, Indication, Diagnostic Tests and Region – ResearchAndMarkets.com




Cocaine Use Disorder Market Analysis, Trends and Outlook 2025-2032 by Treatment Modality, Treatment Setting, Indication, Diagnostic Tests and Region – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cocaine Use Disorder Market – Global Forecast 2025-2032” has been added to ResearchAndMarkets.com’s offering.

The Cocaine Use Disorder Market is experiencing substantial growth, expanding from USD 1.29 billion in 2024 to USD 1.36 billion in 2025, with projections indicating a CAGR of 5.82% reaching USD 2.03 billion by 2032. This comprehensive market research study sheds light on the evolving dynamics and strategic imperatives within the cocaine use disorder treatment landscape. The report provides essential insights for stakeholders navigating the complexities of treatment modalities, regulatory shifts, and external forces affecting patient outcomes since the late twentieth century.

Transformative Shifts in Treatment Innovation

Recent advances in neurobiological research and digital therapeutics have catalyzed a paradigm shift in treating cocaine use disorder, emphasizing personalized medicine and innovative care models. Regulatory agencies have adopted more adaptive frameworks, enabling expedited implementation of novel therapies. For decision-makers, these advancements present opportunities for strategic planning and capturing competitive advantages through emerging technologies.

Telehealth platforms and mobile solutions have further expanded the reach of behavioral therapies, generating real-world data to refine treatment algorithms. Such integrative approaches underscore the market’s progression toward sustainable outcomes.

Key Takeaways from This Report

• Identifies high-impact opportunities for decision-makers within the cocaine use disorder treatment market.
• Offers insights into emerging trends and innovative care models driving sustainable patient outcomes.
• Highlights the importance of strategic partnerships and regional diversification in mitigating tariff impacts.
• Provides direction for leveraging supply chain resilience and data-driven execution in market strategies.

Market Segmentation & Coverage

The report forecasts revenues and analyzes trends in segmentation by treatment modality, setting, indication, diagnostic testing, payer type, provider network, and regional dynamics. The following detailed breakdowns are examined:

• Treatment Modality
  • Behavioral Therapy
    • Cognitive Behavioral Therapy
    • Contingency Management
    • Motivational Interviewing
  • Combined Therapy
    • Integrated Programs
    • Sequential Programs
  • Pharmacotherapy
    • Antidepressants
      • Selective Serotonin Reuptake Inhibitors
      • Serotonin-Norepinephrine Reuptake Inhibitors
    • Psychostimulants
• Treatment Setting
  • Inpatient
    • Detoxification
    • Residential Rehabilitation
  • Outpatient
• Indication
  • Acute
  • Chronic
• Diagnostic Tests
  • Cardiovascular Examination
  • Neurologic Examination
  • Urine Toxicology Examination

Key Attributes

The companies profiled in this Cocaine Use Disorder market report include:

• Alkermes PLC
• Alnylam Pharmaceuticals, Inc.
• Camurus AB
• Embera NeuroTherapeutics, Inc.
• Indivior PLC
• Johnson & Johnson Services, Inc.
• KemPharm, Inc.
• Kinoxis Therapeutics
• Novartis International AG
• Orexo AB
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Polpharma SA
• Revive Therapeutics Ltd.
• Sage Therapeutics, Inc.
• Saniona AB
• Shionogi & Co., Ltd.
• Sigmapharm Laboratories, LLC
• STALICLA SA
• Teva Pharmaceuticals USA, Inc.
• Viatris Inc.
• Mylan Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/r/mg5h70

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

FDA Grants Breakthrough Therapy Designation to Investigational Drug Adrabetadex for Individuals with Infantile-Onset Niemann-Pick Disease Type C




FDA Grants Breakthrough Therapy Designation to Investigational Drug Adrabetadex for Individuals with Infantile-Onset Niemann-Pick Disease Type C

• Breakthrough Therapy Designation is based on FDA’s review of survival analyses comparing adrabetadex-treated patients with external controls and marks a significant regulatory milestone ahead of an NDA submission.

THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Beren Therapeutics P.B.C.®, a Public Benefit Corporation and parent company of Mandos LLC®, today announced that Mandos received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for adrabetadex, an investigational drug for infantile-onset Niemann-Pick disease type C (NPC).

BTD is granted by the FDA to expedite the development of drugs for serious or life-threatening conditions when preliminary clinical evidence may indicate a substantial improvement over existing therapy. The FDA decision was informed by an externally controlled survival analysis that showed adrabetadex improves survival in individuals with infantile-onset NPC and was reviewed alongside supportive biomarker and nonclinical data.

Adrabetadex previously received BTD in 2016 under a prior sponsor, and the FDA rescinded the designation based on data from a 12-month Phase 2b/3 clinical trial. Beren, through its subsidiary Mandos, acquired the adrabetadex program from Mallinckrodt in 2021 and has worked closely with the FDA and NPC community to advance adrabetadex’s development and generate the data and analyses that supported the new BTD designation.

“This newly granted designation represents an important milestone in the evaluation of adrabetadex for people living with infantile-onset NPC,” said Jason Camm, Chief Executive Officer of Beren Therapeutics P.B.C. “We are grateful to the people living with NPC and their caregivers, clinicians, and advocates who have worked with us through a long development path.”

Dr. Elizabeth Berry-Kravis, Professor of Pediatrics at Rush University Medical Center and principal EAP investigator, noted: “Infantile-onset NPC is a devastating, rapidly fatal diagnosis. Seeing statistically significant improvements in survival signals a meaningful shift in what is achievable for these patients.”

Adrabetadex also has Orphan Drug and Rare Pediatric Disease designations. Beren plans to submit an NDA in the near future and expects adrabetadex to be eligible for Priority Review.

About Niemann-Pick Disease Type C

Niemann-Pick disease type C (NPC) is a rare, autosomal-recessive, severe, neurodegenerative disorder caused by pathologic variants in the NPC1 (~95% of cases) or NPC2 genes, leading to impaired cholesterol trafficking resulting in progressive neurological decline and premature death. Infantile-onset NPC refers to NPC in individuals who first experience neurological symptoms between 0 and 6 years of age. Earlier neurological onset is associated with more rapid progression and poorer prognosis, with mean survival of ~5.6 years for early-infantile-onset (age of neurological onset <2 years) and ~13.4 years for late-infantile-onset (2 to <6 years). Individuals with early- and late-infantile-onset NPC typically present with manifestations affecting multiple organs, with the most severe and debilitating effects occurring in the brain.

About Adrabetadex (VTS-270)

Adrabetadex (VTS-270) is a proprietary mixture of 2-hydroxypropyl-β-cyclodextrin isomers under investigation as a treatment for Niemann-Pick disease type C (NPC). By re-establishing intracellular cholesterol trafficking, adrabetadex directly addresses the underlying pathology of NPC. Adrabetadex is generally well tolerated. The main adverse events associated with adrabetadex include hearing impairment that can be managed with hearing aids when necessary, and post-dose fatigue and/or ataxia.

Adrabetadex has not been approved by the FDA or any other health authority at this time.

About Beren Therapeutics P.B.C. and Mandos

Beren Therapeutics P.B.C. is a founder-led, clinical-stage biotechnology company pioneering the discovery, development, and commercialization of cyclodextrin-based therapeutics for conditions characterized by defective cholesterol trafficking.

Beren and its subsidiary, Mandos, are committed to the development of adrabetadex for individuals living with Niemann-Pick disease type C (NPC), a condition characterized by defects in intracellular cholesterol trafficking. Beren and Mandos have supported the NPC community by providing access to adrabetadex* through an Expanded Access Program (EAP). Beren will continue working closely with patients, families, researchers, regulators and others on a path to bring forth this potentially transformative, investigational therapy for NPC.

Beren is headquartered in Thousand Oaks, CA, and will launch its website out of stealth mode in Q1 2026. For more information, please visit our public-facing subsidiary Mandos.

* Adrabetadex is an investigational drug that has not been approved by the U.S. Food and Drug Administration and has not been found safe and effective to treat NPC or any other condition.

Contacts

Amanda Eckel

BGB Group

Aeckel@bgbgroup.com

Plant Breeding and CRISPR Plants Industry Trends and Market Outlook 2025-2030 – Increasing Regulatory Support for Gene-Edited Crops Spurs Adoption of CRISPR in Mainstream Plant Breeding Programs – ResearchAndMarkets.com




Plant Breeding and CRISPR Plants Industry Trends and Market Outlook 2025-2030 – Increasing Regulatory Support for Gene-Edited Crops Spurs Adoption of CRISPR in Mainstream Plant Breeding Programs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Plant Breeding and CRISPR Plants – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering.

The global market for Plant Breeding and CRISPR Plants was valued at US$21.7 Billion in 2024 and is projected to reach US$50.1 Billion by 2030, growing at a CAGR of 15% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Plant Breeding and CRISPR Plants market.

The growth in the plant breeding and CRISPR plants market is driven by several critical factors that are transforming the agriculture and biotech industries. First, the increasing demand for food security in a world facing population growth and resource constraints is a major driver. CRISPR technology enables the development of crops that can deliver higher yields and resist environmental stressors, helping to meet the rising food demand. Advances in genetic research and biotechnology have made CRISPR more accessible and efficient, reducing the time and cost associated with developing new crop varieties.

Another factor is the growing focus on sustainable agriculture, as both consumers and governments demand more environmentally friendly farming practices. CRISPR allows for the creation of crops that require fewer inputs, such as water and fertilizers, reducing the environmental footprint of farming. Furthermore, regulatory support is playing a crucial role in the market’s expansion, as several countries are moving towards less stringent regulations for CRISPR-edited plants compared to traditional GMOs, which helps to accelerate the adoption of CRISPR technologies.

The increasing investment in agricultural biotechnology, driven by both public and private sectors, is further fueling the market’s growth. Major agricultural biotech companies, research institutions, and startups are heavily investing in CRISPR-based research to create new crop varieties with desirable traits.

Additionally, consumer preferences for healthier, non-GMO food products are influencing market dynamics, as CRISPR plants are often viewed more favorably by consumers compared to traditional GM crops. Together, these factors are creating a strong growth environment for the plant breeding and CRISPR plants market, positioning it as a key component of the future of agriculture.

Report Scope

The report analyzes the Plant Breeding and CRISPR Plants market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

• Segments: Type (Conventional Breeding, Biotechnological Method); Trait (Herbicide Tolerance, Disease Resistance, Yield Improvement, Other Traits); Application (Cereals & Grains, Oilseeds & Pulses, Fruits & Vegetables, Other Applications).
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Regional Analysis

Gain insights into the U.S. market, valued at $5.9 Billion in 2024, and China, forecasted to grow at an impressive 14.4% CAGR to reach $7.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Key Questions Answered:

• How is the Global Plant Breeding and CRISPR Plants Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Advanta Seeds, Bayer, Benson Hill Biosystems, Bioconsortia, DLF and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 23 companies featured in this Plant Breeding and CRISPR Plants market report include:

• Advanta Seeds
• Bayer
• Benson Hill Biosystems
• Bioconsortia
• DLF
• Dow, Inc.
• DuPont de Nemours, Inc.
• Equinom
• Eurofins
• Evogene
• Groupe Limagrain
• Hudson River Biotechnology
• KWS
• Land O’lakes
• Pacific Biosciences
• SGS
• Syngenta

This edition integrates the latest global trade and economic shifts into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes historical analysis from 2015 to 2023.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.

Key Attributes

Market Overview

• Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
• How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind
• Global Economic Update
• Plant Breeding and CRISPR Plants – Global Key Competitors Percentage Market Share in 2025 (E)
• Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)

Market Trends and Drivers

• Rising Demand for High-Yield, Climate-Resilient Crops Drives Adoption of CRISPR and Gene-Editing Technologies in Plant Breeding
• Growing Global Focus on Food Security and Crop Optimization Expands Market for Advanced Plant Breeding Tools and CRISPR Technologies
• Increasing Regulatory Support for Gene-Edited Crops Spurs Adoption of CRISPR in Mainstream Plant Breeding Programs
• Emergence of CRISPR as a Game-Changer in Precision Plant Breeding Propels Demand for Gene-Editing Solutions
• Growing Demand for Pest-Resistant and Disease-Resilient Crops Expands Market for CRISPR Applications in Plant Breeding
• Technological Advancements in Genomics and DNA Sequencing Drive Growth in Precision Plant Breeding Using CRISPR
• Increasing Focus on Reducing Pesticide and Herbicide Use Drives Market for Gene-Edited Crops with Built-In Pest Resistance
• Rising Demand for Biofortified Crops to Address Nutritional Deficiencies Expands Market for CRISPR-Enhanced Plant Breeding
• Increasing Interest in Developing Drought-Resistant and Climate-Adapted Crops Drives Growth of CRISPR Applications in Plant Breeding
• Growing Investment in Agricultural Biotechnology and Gene Editing Expands Opportunities for CRISPR Technology in Commercial Plant Breeding
• Increasing Consumer Demand for Non-GMO, Gene-Edited Crops Spurs Growth of CRISPR Plant Breeding Solutions
• Advances in Molecular Breeding Techniques and Marker-Assisted Selection Expand Applications of CRISPR in Plant Genetics

For more information about this report visit https://www.researchandmarkets.com/r/vg1d9p

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

New Frontiers for Early-life Nutrition: All G and Armor Protéines Announce Joint Venture to Scale Human and Bovine Lactoferrin as All G Closes A$10 Million Round




New Frontiers for Early-life Nutrition: All G and Armor Protéines Announce Joint Venture to Scale Human and Bovine Lactoferrin as All G Closes A$10 Million Round

SYDNEY–(BUSINESS WIRE)–Australian biotech All G has raised over A$10 million in a convertible note round ahead of its Series B raise, injecting additional capital for commercial-scale production of its first bovine lactoferrin product due to launch in Q1 2026.

In parallel, All G and French global bioactives leader Armor Protéines have established a joint venture (JV) to produce and commercialise human and bovine lactoferrin.

One of the most powerful functional milk proteins, lactoferrin’s antimicrobial properties and ability to support iron absorption have led to applications across infant nutrition, nutraceuticals, personal care, and therapeutics.

The JV will combine All G’s world-leading precision fermentation platform and deep scientific capabilities, with Armor Protéines’ expertise in high-value, bioactive functional milk proteins, to transform how lactoferrin is made, purchased and consumed. The inclusion of human lactoferrin in the JV represents a pathway to creating infant formulas that more closely reflect the protein profile of breast milk.

A new way to meet global lactoferrin demand

Lactoferrin is a multifunctional protein found in both human and cow’s milk. It offers health benefits across the lifespan, playing critical roles in immune function, iron homeostasis, and gastrointestinal and dermatological health.

Lactoferrin is traditionally extracted from cow’s milk, requiring thousands of litres of milk to yield just one kilogram of lactoferrin. As a result, lactoferrin remains one of the most expensive functional ingredients and is used only in a limited proportion of infant formula products, primarily in premium and super premium formulations.

The development of recombinant lactoferrin as an alternative to animal-based production has long been constrained by technical barriers – notably replicating native glycosylation patterns and achieving yields sufficient for commercial viability. All G has overcome these hurdles, enabling the production of lactoferrin with high purity, consistent quality, scalable production, and ultimately greater global accessibility.

Bringing human milk proteins to market

All G’s human lactoferrin will be bio-equivalent to the native form with greater than 95% purity. As the company’s first recombinant human milk protein, it marks a step toward improving early life nutrition, bringing infant formula closer to the composition of human milk.

Armor Protéines’ deep expertise in bioactives, large-scale ingredient manufacturing and commercialization of infant formula ingredients, and long-standing relationships with world-leading nutrition companies position the JV to scale human lactoferrin production rapidly and reliably across global nutrition markets.

Progressing quickly to commercial launch

Pilot-scale production of All G’s recombinant bovine lactoferrin is already complete. The company has already self-affirmed GRAS status for adult nutrition sales in the US and approval for personal care sales in China, with further filings underway.

About All G

All G is an Australian biotech developing next-generation human and bovine milk proteins using precision fermentation technology. Focusing on high-value recombinant proteins, the company has filed multiple patents covering its proprietary compositions and processes, including micelle assembly, scalable manufacture, and applications in human milk compositions.

All G’s first product, a bovine lactoferrin powder, will launch in late 2025 and will be followed by human lactoferrin in early 2026.

About Armor Protéines

Armor Protéines, a subsidiary of Savencia Fromage & Dairy, is a global producer of lactoferrin, supplying high-purity proteins to the infant formula, adult nutrition, and health supplement industries for over 30 years. Armor Protéines’ long-standing customer relationships, scientific expertise and deep experience in distribution make it a preferred partner for next-generation nutrition ingredients.

Contacts

ALL G CO PTY LIMITED

723-725 ELIZABETH ST WATERLOO NSW AUSTRALIA 2017

shae@allg.com

Hims & Hers Brings Comprehensive Weight Loss Programme to the UK




Hims & Hers Brings Comprehensive Weight Loss Programme to the UK

Expansion Debuts Hers, Unlocking Personalised Care for British Women

LONDON–(BUSINESS WIRE)–Hims & Hers is deepening its commitment to the UK by bringing access to its comprehensive Weight Loss Programme to customers. This expansion includes the official introduction of the Hers platform, helping eligible women across the UK receive access to this holistic weight management care.

Sixty four percent of UK adults are overweight or living with obesity, yet access to GLP-1 treatment plans remains challenging on the NHS, and via the private sector due to surging demand and escalating costs. Removing barriers to care, the Hims & Hers digital platform provides eligible British women and men seamless access to its comprehensive, doctor-designed Weight Loss Programme.

Following a thorough, and clinically robust intake assessment conducted by GMC-registered doctors, eligible customers now have access to transparent pricing and personalised weight management programmes, which may include branded GLP-1 options, such as Mounjaro or Wegovy, and the oral non-prescription treatment option, Orlos. Licensed clinicians assess each individual’s medical history, suitability, and contraindications to guide appropriate treatment decisions. Critically, all customers have access to comprehensive support, including 24/7 care team access and content to help improve nutrition, movement, and sleep-based habits along their weight loss journey. This holistic programme is designed to support long-term health, helping customers manage their weight and adopt sustainable lifestyle habits.

Now for the first time through Hers, women in the UK deemed clinically suitable can access a new standard of weight management care that blends convenience with personalised support at every step of their journey. Hers’ customers receive ongoing clinician support through follow-ups and asynchronous messaging, along with treatment adjustments when necessary, keeping care seamless, conversational, and customer-centered. Hers is more than just a telehealth platform; it’s where clinical experience meets thoughtful care, resetting women’s expectations and standards for comprehensive and convenient care.

“The launch of Hims & Hers’ comprehensive Weight Loss Programme and the vital introduction of the Hers platform, our dedicated platform for women, represents a significant deepening of our commitment to the UK,” said David Meinertz, GM International of Hims & Hers. “Our doctor-designed treatment plans will complement the NHS by providing accessible, evidence-based, and sustainable long-term weight management care to those who need it, discreetly and conveniently. Our proven model is grounded in clinical excellence, oversight, and convenience, ensuring that every customer receives the thoughtful, thorough, and high-quality care they deserve.”

“Obesity is a global epidemic, and the scale of the challenge in the UK requires a comprehensive solution that prioritises long-term health over quick fixes,” said Craig Primack MD, Head of Weight Loss at Hims & Hers. “Bringing our trusted, comprehensive approach to the UK will help people lead fuller and healthier lives. And with the launch of the Hers platform, we are ensuring women have access to the dedicated, personalised care they need. Pairing clinically-proven treatments like GLP-1s with holistic support across nutrition and exercise helps make sustainable weight management achievable for the millions battling obesity today.”

Launching its Weight Loss Programme marks the company’s continued progress in its mission to make personalised care accessible to millions of people across the UK. Hims & Hers plans to continue to expand into more offerings as demand for access to personalised care continues to grow.

About Hims & Hers Health, Inc

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalises health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy achievable. No two people are the same, so the company provides access to personalised care designed for progress. For more information, please visit www.forhims.co.uk and www.forhers.co.uk

Cautionary Note Regarding Forward-Looking Statements

This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “project,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding our launch and expansion of the program, the introduction of the Hers platform in the UK, our expectations regarding customer adoption and subscriber growth, the pricing and availability of GLP-1 or other treatment options, our market opportunity in the UK, the growth of our weight management offering internationally, and our ability to comply with applicable legal, regulatory, and clinical requirements in the UK and other markets. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions, and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the performance and acceptance of our weight loss specialty in the UK; our ability to successfully launch and scale the Hers platform in the UK; uncertainties relating to the availability, pricing, or supply of GLP-1 medications; changes in medical guidelines or regulatory requirements in the UK; competitive developments; operational and marketing costs; the impact of macroeconomic conditions on consumer demand; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other reports we file from time to time with the Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of December 10, 2025. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements in this communication.

Contacts

Susan Cadrecha

press@forhims.com

Poxel Publishes Its Financial Results for the First Half of 2025




Poxel Publishes Its Financial Results for the First Half of 2025

• Revenue nearly doubled (+88%) and net loss reduced to €2.6 million in the first half of 2025
• Change in governance on August 1, 2025, following the filing of a declaration of insolvency and a request to open receivership proceedings with the Lyon Commercial Court (Tribunal des activités économiques)
• Commencement of receivership proceedings decided at the hearing on August 5, 2025, with a six-month observation period running until February 5, 2026
• Poxel’s recovery plan, now finalized, is subject to the decision of the Lyon Commercial Court, which is expected early 2026
• The Statutory Auditors are expected to issue a disclaimer opinion (impossibilité de certifier) regarding Poxel’s 2025 half-year condensed financial statements, given the pervasive uncertainty that could call into question the going concern assumption resulting from the aforementioned receivership proceedings – their report will be issued on Poxel’s website at a later date
• As a reminder, the shareholders’ general meeting will be held on December 11, 2025

LYON, France–(BUSINESS WIRE)–Regulatory News:

POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases (the “Company“), announces today its condensed consolidated half-year financial results for the period ended June 30, 2025 and provides an update on recent events ahead of its annual general meeting on December 11, 2025.

First Half 2025 Consolidated Financial Statements (IFRS Standards)

Income statement (limited review procedures by auditors still ongoing)

*Net of R&D tax credit.

Poxel generated revenue of €2.183 million in the first half of 2025, compared to €1.162 million during the same period in 2024, corresponding mainly to ¥345 million in royalties received from Sumitomo Pharma, representing 10% of net sales of TWYMEEG^® in Japan for the first quarter and 8% for the second quarter of 2025.

Cost of sales amounted to €1.877 million as of June 30, 2025, corresponding to the 8% royalties on net sales of Imeglimine in Japan due to Merck Serono, under the Merck Serono license agreement.

Net R&D expenses amounted to €508 thousand for the first half of 2025, compared to €521 thousand for the same period in 2024.

General and administrative expenses amounted to €1.762 million for the first half of 2025, compared to €3.205 million for the same period in 2024, reflecting in particular the cost-saving plan implemented by the Company.

The financial result was negative at €653 thousand for the first half of 2025, compared with a loss of €3.548 million in the first half of 2024. This is mainly due to interest on the Company’s indebtedness (€5.037 million), offset by a foreign exchange gain related to the valuation of the OrbiMed debt at the close of June 30, 2025 (€4.317 million).

The net loss for the financial period ending June 30, 2025, came to €2.617 million, compared with a net loss of €7.258 million for the corresponding half-year period in 2024.

The Company will make the half-year financial report available after the limited review procedures have been completed, enabling the Statutory Auditors to issue their report, in which they are expected to state that they are unable to conclude on the condensed consolidated half-year financial statements due to significant uncertainty that may call into question the Company’s ability to continue as a going concern.

Context for the preparation of the condensed consolidated half-year financial statements as of June 30, 2025

Following the commencement of receivership proceedings on August 5, 2025, the Company will continue to operate during the six-month observation period (starting August 5, 2025), with financing provided by IPF Partners under the following conditions:

• temporary waiver, for the observation period, of the current defaults under the IPF agreement preventing the release of tranche D;
• provision of a portion of tranche D in increments of €500,000 up to a maximum amount of €2.5 million, with the objective of covering cash requirements for the observation period ending February 5, 2026. These drawdowns are conditional upon the presentation of justified financing requirements.

This situation creates significant uncertainty about the Company’s ability to continue as a going concern beyond this point, as it does not currently have sufficient financial resources to cover a twelve-month period.

On December 9, 2025, the Board of Directors approved the Company’s condensed consolidated financial statements for the six months ended June 30, 2025, in accordance with the going concern principle, based on the assumption that the continuation plan developed by the Company with the support of its long-standing financial partner IPF, which was presented in the press release dated November 24, 2025, will be deemed sufficient and approved by all parties concerned, including the shareholders meeting on December 11, 2025, to approve, in particular, the financial delegations necessary to implement the plan and obtain new sources of financing.

As previously indicated in connection with the approval of the financial statements for the year ended December 31, 2024, due to the uncertainties surrounding the going concern of the Company, which is currently in receivership, and after the completion of their limited review procedures, the Statutory Auditors will issue their report in which they are expected to express their inability to conclude on the condensed consolidated half-year financial statements.

Significant events after the balance sheet date

Commencement of receivership proceedings

On July 29, 2025, POXEL announced in a press release that it had filed for receivership with the Lyon Commercial Court (Tribunal des activités économiques de Lyon) and requested the commencement of receivership proceedings.

Following a hearing held on August 5, 2025, the Lyon Commercial Court decided to initiate receivership proceedings.

The Company will continue to operate during the six-month observation period, in accordance with legal provisions. During this period, POXEL will examine all options that would enable it to continue its activities, including a continuation plan.

Change in governance

At its meeting on July 31, 2025, the Company’s Board of Directors decided to replace them individually by co-optation, with immediate effect, with the following new directors:

1. Sophie Jacq Lapointe;
2. Nicolas Trouche, also appointed Chief Executive Officer, replaced on October 31, 2025 by Yves Decadt;
3. Amit Kohli;
4. Alexandre Bragadir.

These co-optations will be submitted for ratification at the Company’s next Annual General Meeting of Shareholders, scheduled for December 11, 2025.

Appointment of Yves Decadt as member of Poxel’s Board of Directors

On October 31, 2025, POXEL announced the appointment of Yves Decadt as a member of the Board of Directors, with the prior resignation of Nicolas Trouche from his position as director in order to comply with the minimum proportion of directors of each gender.

Yves Decadt has over 25 years of international experience in the pharmaceutical industry. He spent nearly 20 years at Johnson & Johnson in the international business development department, where he was responsible for licensing and agreement negotiations, particularly in Asia. He has also held several management positions at renowned biopharma and medtech companies. Yves brings to Poxel both scientific and strategic expertise, as well as access to a vast international network. Under a consulting agreement, Yves has been working with the POXEL teams since August 2025 on ongoing partnership discussions and on evaluating the commercial development potential of Poxel’s key assets.

TWYMEEG^® sales for the quarter ended September 30, 2025

For the quarter ended September 30, 2025, gross sales of TWYMEEG^® in Japan reached ¥2.6 billion (€15 million¹), compared to ¥1.8 billion (€11.4 million) for the third quarter of 2024.

As a reminder, for the full financial year 2025, Sumitomo Pharma forecasts gross sales of TWYMEEG^® of ¥11.2 billion (€64.4 million⁴), which would represent an increase of 47% compared to 2024.

Based on these forecasts for financial year 2025, TWYMEEG^® would therefore reach the milestone of net sales of ¥10 billion (€57.5 million), enabling Poxel to receive royalties of 12% on all net sales of TWYMEEG^® as well as a second payment of ¥1 billion (€5.8 million³) based on sales. However, in accordance with the monetization agreement entered into with OrbiMed, these cash flows will be allocated in full to the repayment of the bond loan. Beyond 2025, Poxel anticipates double-digit royalty growth and additional payments contingent upon the achievement of contractual milestones. However, in accordance with the monetization agreement entered into with OrbiMed, these cash flows will be allocated entirely to the repayment of the bond loan.

Finalization of the recovery plan

Poxel’s draft recovery plan has been finalized and remains subject to the decision of the Lyon Commercial Court. As a reminder, Poxel has a new management team and a board of directors with experience in biotech, whose role is to implement the draft recovery plan. This includes Yves Decadt who has conducted a strategic review of Poxel’s portfolio to help develop this draft plan, whose priorities in terms of commercial development are as follows:

• Establish new partnerships to commercialize Imeglimine in Asia, with priority given to China and countries that do not require new clinical studies;
• Promote PXL770 in ADPKD; and
• Promote PXL065 in HCM.

Poxel’s new management team is fully committed to implementing this recovery plan and seeking partnerships to monetize Poxel’s assets in order to recreate value for the Company’s shareholders.

Annual General Meeting of the Company to be held this Thursday, December 11, 2025

As a reminder, on November 5, 2025, Poxel published a meeting notice and on November 26, 2025, a notice of meeting to convene its shareholders on December 11, 2025, for its Annual General Meeting, to decide, in particular, on the 2024 annual and consolidated financial statements, as well as on various financial delegations to the Board of Directors, some of which are intended to enable the implementation of certain capital transactions aimed at strengthening the Company’s financial structure in order to support its business plan.

The full text of the resolutions submitted to the shareholders’ meeting of December 11, 2025, was published in the Bulletin des Annonces Légales Obligatoires (BALO) No. 142 of November 26, 2025.

All preparatory documents and information relating to this General Meeting are available to shareholders in accordance with legal and regulatory requirements and can be found on the Company’s website, under the heading “General Meeting.”

In accordance with current regulations, Poxel shareholders may cast their votes prior to the General Meeting from November 26, 2025, by mail, proxy, or electronically, in accordance with the procedures set out in the meeting notice published in the BALO on November 5, 2025, as reproduced in the notice of meeting published on November 26, 2025.

The option to vote or grant proxy electronically is available via the secure voting platform Votacess, which will open on November 26, 2025, at 9:00 am (Paris time) and close on December 10, 2025, at 3:00 pm (Paris time).

Voting instructions are also detailed in the practical guide available to shareholders on the Company’s website.

For any questions regarding voting procedures, you may contact the Investor Relations team by email: investors@poxelpharma.com.

Shareholders willing to follow the General Meeting but unable to attend in person are invited to connect via the following link (the General Meeting will be held in French): click here.

About Poxel SA

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized Rpioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG^® (Imeglimin), Poxel’s first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and 5 sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: www.poxelpharma.com

All statements other than statements of historical fact included in this press release concerning future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, but are not limited to, any statements preceded, followed or including words such as “objective,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “may have,” “likely,” “should,” “could” and other words and terms of similar meaning, or the negative form of these words and terms. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to differ materially from the results or performance expected, expressed or implied in such forward-looking statements. Actual events or results may differ from those described in this document due to a number of risks or uncertainties described in the Company’s 2024 Universal Registration Document available on the Company’s website and on the website of the AMF (https://www.amf-france.org/fr). The Company does not endorse or accept responsibility for the content of external hyperlinks mentioned in this press release.

This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to purchase securities in any jurisdiction.

Glossary

You will find below a list of words and/or expressions that are used in this press release or in Poxel’s communication, with the aim to bring clarification and transparency:

• Sumitomo Pharma financial year runs April to March. As an example, Financial Year 2025 is April 1, 2025, through March 31, 2026.
• TWYMEEG^® royalties: As per the Sumitomo Pharma’s agreement, Poxel is entitled to receive royalties from the sales of TWYMEEG^® (Imeglimin) in Japan
  • Sumitomo Pharma communicates gross sales of TWYMEEG^®, while TWYMEEG^® royalties are calculated on net sales.
  • Net sales represent the amount of gross sales to which are deducted potential rebates, allowances, and costs such as prepaid freight, postage, shipping, customs duties and insurance charges.
  • Poxel is entitled to receive escalating royalties of 8-18% on TWYMEEG^® net sales from Sumitomo Pharma.
• Positive net royalties: as part of the Merck Serono licensing agreement, Poxel 6 will pay Merck Serono a fixed 8% royalty based on the net sales of TWYMEEG^®, independent of the level of sales. All royalties that Poxel receives from TWYMEEG^® net sales above that 8% level are considered as positive net royalties. Net royalties will therefore be positive for Poxel when TWYMEEG^® net sales exceed JPY 5 billion in a financial year and royalties reach 10% and above.

¹ Based on an exchange rate of 1 euro to 173.8 yen as of September 30.

⁴ Sumitomo Pharma’s 2025 financial year ends on March 31, 2026.

Contacts

Contacts – Investor relations / Media

NewCap

Théo Martin / Arthur Rouillé

investors@Poxelpharma.com
+33 1 44 71 94 94